FDA Warns of Name Confusion for 2 Breast Cancer DrugsFDA Warns of Name Confusion for 2 Breast Cancer Drugs

The use of a truncated version of the generic name for Kadcyla (ado-trastuzumab emtansine) invites a potentially harmful mix-up with Herceptin (trastuzumab), the FDA has warned. News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news